7/102 sources · 2 publishersUpdated Oct 23, 11:56 UTC
Bank of America upgrades Pharvaris to Buy with $44 price target
Bank of America Securities raised its rating on Pharvaris B.V. (PHVS) from Neutral to Buy and kept a $44 price target. The upgrade follows positive Phase 3 data for the company’s oral HAE drug deucrictibant. The stock was trading around $30.68 and rose about 3% in pre‑market trading after the announcement.
Why it matters
The upgrade suggests analysts see significant upside, which could attract buying interest and lift the share price toward the $44 target. The rating change also highlights the market relevance of Pharvaris’ oral HAE therapy.
Key facts
- 1Bank of America upgraded Pharvaris to Buy from Neutral and maintained a price target of $44.00. investing.com
- 2Pharvaris shares were trading at $30.68 at the time of the upgrade. investing.com
- 3The stock gained 10.6% over the past week. investing.com
- 4Pharvaris shares rose about 3% in pre‑market trading after the upgrade. seekingalpha.com
- 5The upgrade was driven by positive Phase 3 prophylactic data for the oral drug deucrictibant. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.